国: カナダ
言語: 英語
ソース: Health Canada
TELMISARTAN; HYDROCHLOROTHIAZIDE
PRO DOC LIMITEE
C09DA07
TELMISARTAN AND DIURETICS
80MG; 25MG
TABLET
TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 25MG
ORAL
30/100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0244783002; AHFS:
MARKETED
2012-11-22
_ Telmisartan-HCTZ _ _Page 1 of 61_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TELMISARTAN-HCTZ Telmisartan/Hydrochlorothiazide Tablets Tablet, 80 mg / 12.5 mg and 80 mg / 25 mg, Oral USP Angiotensin II AT 1 Receptor Blocker/Diuretic PRO DOC LTÉE. 2925, boul. Industriel Laval, Quebec H7L 3W9 Submission Control Number: 270403 Date of Initial Authorization: NOV 01, 2012 Date of Revision: JAN 9, 2023 _ Telmisartan-HCTZ _ _Page 2 of 61_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Ophthalmologic 05/2022 4 DOSAGE AND ADMINISTRATION 01/2023 7 WARNINGS AND PRECAUTIONS 01/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................. 5 4 DOSAGE AND ADMINISTRATION ...................................................................................... 5 4.1 Dosing Considerations ................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ......................................... 完全なドキュメントを読む